The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
An orally bioavailable tyrosine kinase inhibitor of the BCR-ABL fusion oncoprotein, with potential antineoplastic activity. Upon oral administration, metatinib tromethamine may inhibit the BCL-ABL protein, which may lead to decreased proliferation and enhanced apoptosis in tumor cells. BCR-ABL oncoprotein is generated by a reciprocal translocation between chromosome 9 and 22 specifically t(9;22)(q34;q11). The resulting fusion gene produces proteins with constitutively active tyrosine kinase activity, which stimulate both abnormal cell division and increased cellular proliferation. This fusion is associated with both chronic myeloid leukemia and acute lymphoblastic leukemia. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonyms:||BCR-ABL tyrosine kinase inhibitor BL001 |